Corrigendum to “Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy”

Table 5

Mean percent of change of all parameters after compared to before treatment among the studied patients with colorectal cancer receiving chemotherapy (treated with recombinant human lactoferrin and not).

Parameter	LF; mean ± SD	Control; mean ± SD
Serum LF (%)	111.17% ± 96.69%	1.65% ± 5.36%
Serum GST enzyme (%)	31.83% ± 19.83%	−0.26% ± 0.41%
INF- (%)	5.12% ± 2.18%	−0.33% ± 0.84%
CEA (%)	−47.45% ± 20.91%	95.92% ± 144.93%
BUN (%)	−28.18% ± 10.47%	7.92% ± 21.44%
Serum creatinine (%)	−5.24% ± 37.15%	13.03% ± 24.20%	0.122
AST (%)	−27.50% ± 15.13%	4.63% ± 29.46%
ALT (%)	−5.66% ± 46.83%	3.97% ± 15.96%	0.457
RBCs (%)	11.65% ± 2.15%	−2.56% ± 5.06%
Hb (%)	17.91% ± 2.76%	−3.75% ± 9.53%
WBCs (%)	21.51% ± 18.27%	−1.40% ± 11.09%
Platelet (%)	18.51% ± 4.56%	−10.38% ± 14.81%
Neutrophil (%)	26.31% ± 2.11%	−1.08% ± 9.33%

Note: significant ( ≤ 0.05).